Precision BioSciences, Inc. (DTIL) P/E Ratio History
Historical price-to-earnings valuation from 2024 to 2024
Loading P/E history...
DTIL Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Precision BioSciences, Inc. (DTIL) trades at a price-to-earnings ratio of -2.1x, with a stock price of $7.48 and trailing twelve-month earnings per share of $-1.81.
The current P/E is 116% below its 5-year average of 12.6x. Over the past five years, DTIL's P/E has ranged from a low of 2.4x to a high of 19.5x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, DTIL trades at a 109% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, DTIL trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our DTIL DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
DTIL P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $21B | 25.5Lowest | 6.01Best | +171%Best | |
| $176B | 26.8 | 12.67 | +7% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
DTIL Historical P/E Data (2024–2024)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q4 | $3.81 | $1.62 | 2.4x | -81% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $8.96 | $0.46 | 19.5x | +55% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $9.73 | $0.61 | 16.0x | +27% |
Average P/E for displayed period: 12.6x
See DTIL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DTIL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DTIL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonDTIL — Frequently Asked Questions
Quick answers to the most common questions about buying DTIL stock.
Is DTIL stock overvalued or undervalued?
DTIL trades at -2.1x P/E, below its 5-year average of 12.6x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does DTIL's valuation compare to peers?
Precision BioSciences, Inc. P/E of -2.1x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is DTIL's PEG ratio?
DTIL PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2024-2024.